Novo Nordisk & United States — Food and Drug Administration
9 shared events · Importance 4 · Last updated Apr 20, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Business
Novo Nordisk: Novo Nordisk's CEO, Lars Fruergaard Jørgensen, is stepping down due to market challenges and a significant decline in its share price, impacting its leadership and market position in the obesity drug market.
May 16, 2025 · 7 articles
Regulatory
Novo Nordisk: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
Business
Novo Nordisk: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
Tech
Novo Nordisk: Novo Nordisk announced positive topline results from its HIBISCUS phase 3 trial for etavopivat, a drug for sickle cell disease, which is expected to lead to regulatory submission and potential market approval, significantly boosting the company's pipeline and market position.
Apr 20, 2026 · 7 articles
NEWSDESK
Explore this relationship live
Track how Novo Nordisk and United States — Food and Drug Administration interact across events, view sentiment trends, and discover connected entities.
Open Dashboard